People: Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

30.40USD
10 Jul 2014
Price Change (% chg)

$0.19 (+0.63%)
Prev Close
$30.21
Open
$29.40
Day's High
$30.52
Day's Low
$29.33
Volume
102,472
Avg. Vol
338,499
52-wk High
$57.89
52-wk Low
$16.78

Search Stocks

Sherman, Matthew 

Brief Biography

Dr. Matthew L. Sherman is Senior Vice President, Chief Medical Officer of Acceleron Pharma, Inc. He joined Acceleron in May 2006 and is our Senior Vice President and Chief Medical Officer. Previously, he served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg® by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an MD from Dartmouth Medical School.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
380,662 -- 618,554 999,216

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Knopf

2,633,880

Kevin McLaughlin

--

Steven Ertel

--

Matthew Sherman

999,216

Ravindra Kumar

--

John Quisel

910,219
As Of 30 Dec 2013
Search Stocks